• Je něco špatně v tomto záznamu ?

Food industrial microbial transglutaminase in celiac disease: treat or trick

Aaron Lerner, Torsten Matthias

. 2015 ; 3 (1) : 1-6.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc15025349

The surge in incidence of celiac disease (CD) is due more to environmental than to genetic changes. It is paralleled by a food industry that is continuously introducing additives to processed products. Microbial transglutaminase (mTG) is an enzyme that deamidates/transamidates proteins, enabling cross-linkage of molecules and revolutionizing the properties of many food products. It belongs to the family of transaminases and tissue transglutaminase (tTG) has been identified as the autoantigen in CD. Both enzymes de/transamidate gluten, the nutritional environmental factor that induces CD. Although several studies have shown that mTG transamidation of wheat flour/gluten can detoxify gluten peptide in vitro, by inhibiting the response to intestinal gliadin, inducing T cells and reducing INFγ production without influencing their main technological properties, a word of caution is advised. The oral challenge of adult CD patients with mTG transamidated flour was found to be only partially effective, not fulfilling expectations, and there have been multiple recent observations that indicate that mTG transamidated flour/gluten could be dangerous to gluten sensitive populations: mTG cross-linking of gluten may be hazardous in CD since the enzyme can deamidate gluten, thus mimicking endogenous tTG, it can link an extensive repertoire of proteins and other macromolecules with immunogenic potential, mTG treated gluten peptides are immunogenic to celiac patients, inducing specific IgA antibodiesand are recognized by gluten-specific humanT cells. Their effect on CD intestinal permeability has not yet been studied. To better understand the actual processes and events, associated with the suggested mTG therapy, long-term ex vivo and in vitro studies are needed. Until then, it is best to respect the data but suspect the safety of the gluten sensitive populations.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc15025349
003      
CZ-PrNML
005      
20151122143952.0
007      
ta
008      
150727s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.12691/ijcd-3-1-10 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lerner, Aaron $u Pediatric Gastroenterology and Nutrition Unit, Carmel Medical Center, B, Rappaport School of Medicine, Technion-Israel institute of Technology, Haifa, Israel
245    10
$a Food industrial microbial transglutaminase in celiac disease: treat or trick / $c Aaron Lerner, Torsten Matthias
504    __
$a Literatura
520    9_
$a The surge in incidence of celiac disease (CD) is due more to environmental than to genetic changes. It is paralleled by a food industry that is continuously introducing additives to processed products. Microbial transglutaminase (mTG) is an enzyme that deamidates/transamidates proteins, enabling cross-linkage of molecules and revolutionizing the properties of many food products. It belongs to the family of transaminases and tissue transglutaminase (tTG) has been identified as the autoantigen in CD. Both enzymes de/transamidate gluten, the nutritional environmental factor that induces CD. Although several studies have shown that mTG transamidation of wheat flour/gluten can detoxify gluten peptide in vitro, by inhibiting the response to intestinal gliadin, inducing T cells and reducing INFγ production without influencing their main technological properties, a word of caution is advised. The oral challenge of adult CD patients with mTG transamidated flour was found to be only partially effective, not fulfilling expectations, and there have been multiple recent observations that indicate that mTG transamidated flour/gluten could be dangerous to gluten sensitive populations: mTG cross-linking of gluten may be hazardous in CD since the enzyme can deamidate gluten, thus mimicking endogenous tTG, it can link an extensive repertoire of proteins and other macromolecules with immunogenic potential, mTG treated gluten peptides are immunogenic to celiac patients, inducing specific IgA antibodiesand are recognized by gluten-specific humanT cells. Their effect on CD intestinal permeability has not yet been studied. To better understand the actual processes and events, associated with the suggested mTG therapy, long-term ex vivo and in vitro studies are needed. Until then, it is best to respect the data but suspect the safety of the gluten sensitive populations.
650    12
$a celiakie $x diagnóza $x dietoterapie $x imunologie $x prevence a kontrola $x terapie $7 D002446
650    _2
$a incidence $7 D015994
650    _2
$a gluteny $7 D005983
650    _2
$a potravinářský průmysl $x metody $x organizace a řízení $x trendy $7 D019649
650    _2
$a mouka $x normy $x škodlivé účinky $7 D005433
650    _2
$a rizikové faktory $7 D012307
650    _2
$a autoimunitní nemoci $x diagnóza $7 D001327
650    _2
$a lidé $7 D006801
653    10
$a mikrobiální transglutaminázy
653    10
$a imunogenicita
653    00
$a tkáňové transglutaminázy
653    00
$a střevní propustnost
700    1_
$a Matthias, Torsten $u Aesku. Kipp Institute, Wendelsheim, Germany
773    0_
$t International journal of celiac disease $x 2334-3427 $g Roč. 3, č. 1 (2015), s. 1-6 $w MED00186448
856    41
$u http://www.sciepub.com/journal/index.aspx?id=ijcd $y domovská stránka časopisu
910    __
$a ABA008 $b B 2748 $c 280 $y 4 $z 0
990    __
$a 20150723102837 $b ABA008
991    __
$a 20151122144019 $b ABA008
999    __
$a ok $b bmc $g 1085556 $s 908355
BAS    __
$a 3
BMC    __
$a 2015 $b 3 $c 1 $d 1-6 $i 2334-3427 $m International journal of celiac disease $x MED00186448
LZP    __
$c NLK185 $d 20151121 $a NLK 2015-19/mk

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...